Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Sep 28, 2024 11:18am
443 Views
Post# 36245336

Algo’s taking a break

Algo’s taking a break Nice to see share price finally moving in the right direction. It's simply amazing how the share price reacts when the shorts take a pause.

We are almost 8 months into dosing at 5 sites in Turkey. Thats 8 months of dosing potentially 100 patients and zero adverse reactions, this is extremely bullish.

This week people who were holding debt agreed to convert debt to shares which is another very bullish indicator.

I believe the group who have been aggressively shorting for the past two years have finally realized they are playing with fire.

My conservative guess is that each Turkish site has approximately 1,000 potential patients and that equates to 5,000 annually combined. We can assume Arch is extremely conservative and that only 3% are considered suitable for participating. That 3% equates to 150 patients annually which is 12.5 patients per month which at 8 months would equate to 100 patients dosed.

If we were to insert a 5% suitable number dosed we would dose 250 patients annually thus trial would be completed in a 12 month period with 8 months already achieved. 5% I think is also reasonable considering 95% would be considered not suitable.

100 Patients should certainly provide a solid indication on how Metablok is working. Please remember we are dosing at a level 4 times higher then previous trial.

We also have Pontiac trial slated to stsrt late 2024 but I suspect it will be 2025 as Canadian sites are notoriously slow on approvals which we know first had with current Metablok phase 2 trial.
<< Previous
Bullboard Posts
Next >>